Acute Respiratory Distress Syndrome Clinical Trial Pipeline Shows Potential With Active Contributions From 40+ Key Companies Delveinsight

A snapshot of the Pipeline Acute Respiratory Distress Syndrome Drugs mentioned in the report:

Learn more about the emerging ARSD therapies @ Acute Respiratory Distress Syndrome Clinical Trials

Stuti Mahajan, consulting manager at DelveInsight, said that ARDS remains a high-burden critical care condition with significant unmet need, driven by its complex pathophysiology and lack of targeted pharmacological therapies. Despite advances in supportive care, mortality remains high, highlighting limited treatment impact. Emerging approaches such as anti-inflammatory and cell-based therapies show promise, but clinical heterogeneity continues to challenge development.

Recent Developments in Acute Respiratory Distress Syndrome Treatment Space

• In February 2026, Edesa Biotech announced positive additional data from a Phase III study of paridiprubart. Par Nijhawan, MD, Chief Executive Officer of Edesa Biotech, stated that the results announced support the central role of TLR4 in hyperinflammatory ARDS and demonstrate a consistent benefit across high-mortality etiologies. The drug is currently being evaluated in a separate US government-funded study of ARDS patients.
• In October 2025, Edesa Biotech, a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics (HDTs) for immuno-inflammatory diseases, announced positive results from a Phase III study evaluating the company's drug candidate paridiprubart (EB05) as a treatment for Acute Respiratory Distress Syndrome. The data from the Phase III study demonstrated that paridiprubart met primary and secondary endpoints with statistical significance.
• In June 2025, BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to its lead product candidate, recombinant human plasma gelsolin (rhu-pGSN) for the treatment of acute respiratory distress syndrome.
• In June 2025, NuvOx Therapeutics announced that the first patient has been dosed for its EXTEND trials: novEl oXygen ThErapeutic NanO2 for mild respiratory distress in Phase Ib and ARDS in Phase II Trials.
• In May 2024, Vasomune Therapeutics announced that the FDA has granted Fast Track designation to AV-001, an investigational drug in development to prevent or treat moderate-to-severe acute respiratory distress syndrome (ARDS) in patients with respiratory infections. According to the company, Phase I data demonstrated the safety and pharmacokinetic profile of AV-001, backing once-daily dosing. Additionally, the treatment showed support for strong Tie2 activation. AV-001 is currently recruiting patients for a Phase IIa trial as an ARDS treatment in pneumonia.
• In November 2023, Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases associated with vascular dysfunction, announced that their lead drug candidate AV-001 has received a positive recommendation from the Independent Data and Safety Monitoring Board (IDSMB) of the AV001-004 Phase IIa Study. The Phase IIa trial (NCT05123755) evaluated the efficacy, safety, and tolerability of AV-001 in patients suffering with Acute Respiratory Distress Syndrome.

Scope of the Acute Respiratory Distress Syndrome Pipeline Report

• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
• Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
• Therapeutics Assessment By Mechanism of Action: Complement C5a inhibitor Mitogen-activated protein kinase 14 inhibitor, Nicotinamide phosphoribosyltransferase inhibitor, CXCR1/ CXCR2 Inhibitor, TIE-2 receptor agonists, CD14 antigen inhibitor, and others.
• Key Acute Respiratory Distress Syndrome Companies:Staidson (Beijing) Biopharmaceuticals Co., Ltd, GEn1E Lifesciences, Aqualung Therapeutics Corp., Dompé Farmaceutici S.p.A., Vasomune Therapeutics, Implicit Bioscience, Edesa Biotech, MiNK Therapeutics, BioAegis Therapeutics, Direct Biologics, AVM Biotechnology, Athersys, EXORPHIA, EnliTISA (Shanghai) Pharmaceutical, LEAF4Life, Savara Pharmaceuticals, Tiziana Life Sciences, Factor Bioscience, LTT Bio Pharma, Orbsen Therapeutics, and others.
• Key Acute Respiratory Distress Syndrome Pipeline Therapies: STSA 1002, GEn 1124, ALT-100, Reparixin, AV-001, Atibuclimab, EB05, AGENT 797, Rhu-pGSN, ExoFlo, AVM0703, Invimestrocel, EXP01, TISA-818, LEAF-4L6715, Molgramostim, TZLS-501, NC-MSC, LT1001, Orbcel C, and others.

Acute Respiratory Distress Syndrome Drugs

Table of Contents

1.	Acute Respiratory Distress Syndrome Pipeline Report Introduction
2.	Acute Respiratory Distress Syndrome Pipeline Report Executive Summary
3.	Acute Respiratory Distress Syndrome Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	Acute Respiratory Distress Syndrome Clinical Trial Therapeutics
6.	Acute Respiratory Distress Syndrome Pipeline: Late-Stage Products (Pre-registration)
7.	Acute Respiratory Distress Syndrome Pipeline: Late-Stage Products (Phase III)
8.	Acute Respiratory Distress Syndrome Pipeline: Mid-Stage Products (Phase II)
9.	Acute Respiratory Distress Syndrome Pipeline: Early-Stage Products (Phase I)
10.	Acute Respiratory Distress Syndrome Pipeline Therapeutics Assessment
11.	Inactive Products in the Acute Respiratory Distress Syndrome Pipeline
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Companies
14.	Key Products in the Acute Respiratory Distress Syndrome Pipeline
15.	Unmet Needs
16.	Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

For further information on the acute respiratory distress syndrome cure research, reach out @ Medication for Acute Respiratory Distress Syndrome Treatment

Related Reports

Acute Respiratory Distress Syndrome Epidemiology Forecast

Acute Respiratory Distress Syndrome Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted ARDS epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Acute Respiratory Distress Syndrome Market

Acute Respiratory Distress Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ARDS companies, including MediciNova, Edesa Biotech, Light Chain Biosciences, Mesoblast Limited, Veru, APEPTICO Forschung und Entwicklung GmbH, Pluristem Therapeutics, Avalo Therapeutics, Boehringer Ingelheim, Genentech, Windtree Therapeutics, Biomarck Pharmaceuticals, Athersys, Healios, Direct Biologics, Biohaven Pharmaceutical, Arch Biopartners, ILTOO Pharma, Cartesian Therapeutics, AVEM HealthCare, Vitti Labs, LLC, GEn1E Lifesciences, MiNK Therapeutics, Longeveron Inc., Reven Pharmaceuticals, Inc., Dompé Farmaceutici S.p.A, Vasomune Therapeutics, Inc., Aerogen Pharma Limited, among others.

Chronic Obstructive Pulmonary Disease Market

Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key chronic obstructive pulmonary disease companies, including Sanofi, Chiesi Farmaceutici S.p.A., United Therapeutics Corporation, Verona Pharma plc, Immunotek, Yungjin Pharm. Co., Ltd., Pulmotect, Inc., Tetherex Pharmaceutical, CSL Behring, AstraZeneca, Novartis, Genentech, Vertex Pharmaceuticals, EmeraMed, Afimmune, Mereo BioPharma, Synairgen, Adamis Pharmaceuticals, Quercegen Pharmaceuticals LLC, Regend Therapeutics, Meridigen Biotech Co., Ltd., Pulmatrix, Eisai, GlaxoSmithKline, EpiEndo Pharmaceuticals, 3SBio, OmniSpirant, Foresee Pharmaceuticals, Amgen, Organicell Regenerative Medicine, Arrowhead Pharmaceuticals, ProterixBio, RS BioTherapeutics, MitoRx, C4X Discovery, Respiratorius, ARK biosciences, Incannex, GNI Pharma, Celon pharma, Alveolus Bio, Kinaset therapeutics, Landos Biopharma, Parion Sciences, KeyMed Biosciences, Bioneer corporation, AlgiPharma, Palobiofarma, Dimerix Bioscience, Glenmark Pharmaceuticals, among others.

Chronic Obstructive Pulmonary Disease Clinical Trial Analysis

Chronic Obstructive Pulmonary Disease Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key COPD companies, including Sanofi, Chiesi Farmaceutici S.p.A., United Therapeutics Corporation, Verona Pharma plc, Immunotek, Yungjin Pharm. Co., Ltd., Pulmotect, Inc., Tetherex Pharmaceutical, CSL Behring, AstraZeneca, Novartis, Genentech, Vertex Pharmaceuticals, EmeraMed, Afimmune, Mereo BioPharma, Synairgen, Adamis Pharmaceuticals, Quercegen Pharmaceuticals LLC, Regend Therapeutics, Meridigen Biotech Co., Ltd., Pulmatrix, Eisai, GlaxoSmithKline, EpiEndo Pharmaceuticals, 3SBio, OmniSpirant, Foresee Pharmaceuticals, Amgen, Organicell Regenerative Medicine, Arrowhead Pharmaceuticals, ProterixBio, RS BioTherapeutics, MitoRx, C4X Discovery, Respiratorius, ARK biosciences, Incannex, GNI Pharma, Celon pharma, Alveolus Bio, Kinaset therapeutics, Landos Biopharma, Parion Sciences, KeyMed Biosciences, Bioneer corporation, AlgiPharma, Palobiofarma, Dimerix Bioscience, Glenmark Pharmaceuticals, among others.

Asthma Market

Asthma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key asthma companies including GlaxoSmithKline, 4D Pharma plc, AstraZeneca, Suzhou Connect Biopharmaceuticals, Avillion, Pearl Therapeutics, ARS Pharmaceuticals, Sinomab, Avalo Therapeutics, Kymab, Sanofi, Cumberland Pharmaceuticals, Genentech, Inc. , among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

CONTACT: Contact Us Shruti Thakur... +14699457679